Incyte (INCY) Tops Q2 EPS by 28c, raises FY23 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts INCY Hot Sheet
Price: $119.81 +1.89%
Financial Fact:
Diluted (in shares): 194.27M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Diluted (in shares): 194.27M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Incyte (NASDAQ: INCY) reported Q2 EPS of $0.99, $0.28 better than the analyst estimate of $0.71. Revenue for the quarter came in at $954.61 million versus the consensus estimate of $911.68 million.
Guidance:
Raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023
For earnings history and earnings-related data on Incyte (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Amgen (AMGN) PT Raised to $530 at UBS
- Stifel Positive on Rapport Therapeutics (RAPP): 'remains on track to share longer-term safety data from the ph2a in 4Q26'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
